EMA PRIME status granted to Janssen’s inherited retinal disease gene therapy
The designation makes the drug the only XLRP treatment in development to be awarded PRIME designation.
Read More
Author: Anna Smith
Largest ever eating disorders study launched in UK
Last year it was revealed that a “record number” of children are being hospitalised for eating disorders.
Read More
Novartis’ ‘life-changing’ Ilaris set for NHS funding
The drug is a more effective, convenient option with fewer side effects than existing treatments.
Read More
CHMP recommends just two new meds in Feb meeting
The committee also noted three extensions of pre-existing therapies.
Read More
Subcutaneous Remsima launched in UK
The new option is the first and only subcutaneous formulation of the drug.
Read More- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
